Preoperative oral pregabalin 150 mg versus 300 mg in total hip arthroplasty: effects on duration of spinal anesthesia and postoperative pain

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202201644616894

Enrollment

129

Registered

2022-01-14

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopaedics Anaesthesia

Interventions

Pregabalin

Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A total of 129 patients scheduled to undergo total hip arthroplasty under spinal anesthesia, aged 40-60 years, and ASA I-II will be enrolled in this study.

Exclusion criteria

Exclusion criteria: Exclusion criteria will include: (1) uncooperative patient, (2) allergy or contraindication to pregabalin, (3) preoperative use of antidepressants or anticonvulsants, (4)preoperative routine use of non-steroidal anti-inflammatory drugs (NSAIDs) or opioids, (5) drug or alcohol abuse, (6) history of diabetes mellitus, (7) impaired kidney function.

Design outcomes

Primary

Measure	Time frame
The primary outcome will be the duration of sensory and motor block	—

Secondary

Measure	Time frame
The secondary outcome will be postoperative morphine consumption, pain score, and occurrence of any side effects.	—

Countries

Egypt

Contacts

Public ContactMohamed Mahmoud

Lecturer Anesthesia and Surgical ICU Faculty of Medicine Mansoura University

drmohamed.mahdy@yahoo.com00201114781275

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026